References
- Review of the Public Health Service’s Response to AIDS OTA-TM-H-24. Congress. Office of Technology Assessment, Washington, DC, USA, 28–29 (1985).
- Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med.361(23), 2209–2220 (2009).
- Rgp120 HIV Vaccine Study Group. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis.191, 654–665 (2005).
- Pitisuttithum P, Gilbert P, Gurwith M et al. Randomized, double-blind placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis.194, 1661–1671 (2006).
- Mascola JR, Snyder SW, Weislow OS et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis.173, 340–348 (1996).
- Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated imunity HIV-1 vaccine (the Step Study): a double-blind, randomized, placebo-controlled test-of-concept trial. Lancet372, 1881–1893 (2008).
- Johnston MI, Fauci AS. AN HIV Vaccine – challenges and prospects. N. Engl. J. Med.359, 888–890 (2008).
- Back to basics. Nat. Med.15(8), 821 (2009).
- Thomas C. Roadblocks in HIV research: five questions. Nat. Med.15(8), 855–859 (2009).
- Gilbert PB, Berger JO, Stablein S et al. Satatistical interpretation of the RV 144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J. Infect. Dis.203, 969–975 (2011).
- Mast TC, Kierstead L, Gupta SB et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine28(4), 950–957 (2010).
- Michael N. Correlates of immunity: RV 144 – lessons learned. Plenary session 3. Presented at: AIDS Vaccine 2010. Atlanta, Georgia, USA, 28 September–1 October 2011.
- Robinson H, Amara R, Lai L, Kozlowski P. Preclinical studies on DNA/MVA vaccines: co-expressed GM-CSF, a strong adjuvant for blocking transmission. S04.05. Presented at: AIDS Vaccine 2010. Atlanta, Georgia, USA, 28 September–1 October 2011.
- Karim QA, Salim, Karim SA, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science329, 1168–1174 (2010).
- Grant RM, Lama JR, Anderson PL et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med.363(27), 2587–2599 (2010).